default author photo

Gary Ulaner

Hoag Family Cancer Institute

SCHOLARLY PAPERS

1

DOWNLOADS

22

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Clinical utility of [18F]fluoroestradiol PET/CT to guide second line treatment decision in ER-positive HER2-negative metastatic breast cancer after progression on first line endocrine therapy

Number of pages: 33 Posted: 06 Jul 2026
Hannah Linden, Sophia R. O'Brien, Stephanie van de Ven, Paul La Porte, Peter S. Conti, Parvin F. Peddi, Joanne Mortimer, Christiana Brenin, Amol M. Takalkar, Julia E. McGuinness, Edgar Cheng, Amol Rao, Lanell M. Peterson, Jennifer Specht, Terence Z. Wong, David A. Buck, Adam Brufsky and Gary Ulaner
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Columbia University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Washington, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Hoag Family Cancer Institute
Downloads 22

Abstract:

Loading...

FES PET, estrogen receptor, metastatic breast cancer, Progression, Endocrine resistance, endocrine therapy, decision-making